Tuesday, June 30, 2026
← Back to archivePolicy
Policy•Fierce Biotech•Jun 30, 2026
Praxis faces FDA decision delay as analysts point finger at agency layoffs
background ▾
- •FDA delays on technical analyses (reclassified as 'major amendments') are now a pattern across multiple sponsors, with timing correlating to April 2025 agency layoffs and continuing into 2026—signaling structural resource constraints at the agency
- •Relutrigine's delay does not reflect clinical or manufacturing deficiencies; the drug showed 53% placebo-adjusted seizure reduction and passed a benign mid-cycle review, positioning it for eventual approval despite the three-month extension
- •Monitor whether FDA capacity issues persist and affect approval timelines for other priority review programs; this pattern may influence investor expectations for 2026 NDA decisions across the industry
Praxis Precision MedicineRhythm PharmaceuticalsKalVista PharmaceuticalsrelutrigineImcivreesebetralstat
→ Read original articlePolicy•Fierce Biotech•Jun 29, 2026
FDA rejects Sobi’s gout drug over manufacturing issues, sparing Amgen blockbuster
background ▾
- •FDA rejection was manufacturing-focused, not clinical; the agency found no efficacy or safety concerns, signaling a pathway to resubmission and eventual potential approval.
- •NASP's monthly IV dosing and lack of methotrexate requirement offer meaningful differentiation from Krystexxa for patients with contraindications (severe hepatic/renal disease), positioning it as a potential blockbuster if manufacturing issues are resolved.
- •Sobi's parallel advancement of pozdeutinurad (oral, once-daily URAT1 inhibitor) with positive Phase 3 topline and blockbuster sales forecasts ($1B+) suggests the company is hedging its gout portfolio against NASP delays and may ultimately offer complementary mechanisms to address the substantial unmet need in refractory gout.
SobiAmgenSelecta BiosciencesNASPKrystexxapegloticase
→ Read original articlePolicy•Fierce Biotech•Jun 29, 2026
United Therapeutics nabs FDA approval for donor-lung assessment device
background ▾
- •FDA PMA approval for LungFX represents a significant regulatory milestone for organ preservation technology with potential to increase donor lung utilization in a resource-constrained transplant system.
- •EVLP technology enables objective re-assessment of marginal donor lungs in controlled conditions, potentially expanding the eligible donor pool and reducing organ waste.
- •Commercial implementation delayed until 2027; actual clinical adoption rates and reimbursement landscape for EVLP services will be critical success factors to monitor.
United TherapeuticsCleveland ClinicLungFX
→ Read original articlePolicy•Fierce Biotech•Jun 29, 2026
Production problems hamper Lantheus bid for FDA approval of radiopharma dx kit
background ▾
- •FDA approval blocked solely by CDMO facility manufacturing/inspection deficiencies, not product science—a potentially remediable but unpredictable regulatory hurdle that could delay market entry by months to over a year
- •No clinical or safety efficacy concerns raised by FDA, preserving the commercial value of LNTH-2501 contingent on CDMO compliance resolution
- •Monitor remediation timeline and FDA re-inspection results; any prolonged manufacturing standoff could weaken Lantheus' negotiating position in the reported ~$7B Curium acquisition talks
LantheusCurium PharmaLNTH-2501Gallium 68 edotreotide
→ Read original articlePolicy•KFF•Jun 30, 2026
Poll: People Without a Trusted Health Care Provider Are More Likely to Endorse Vaccine Myths, As Are Those Who Often Use Social Media or AI for Health Information
background ▾
- •Public health perception gaps exist: 39% of adults without trusted providers endorse MMR-autism myth vs. 24% with providers; social media/AI health information use roughly doubles myth endorsement rates
MMR vaccinemRNA vaccinesCOVID-19 vaccines
→ Read original articleMarket Access
Market Access•Fierce Biotech•Jun 29, 2026
BioCryst ends internal discovery programs, closes Alabama facility in pivot to cost-saving partnerships
background ▾
- •BioCryst is eliminating all internal discovery capabilities and outsourcing innovation entirely—a fundamental business model shift that prioritizes near-term cost savings ($30M) over long-term discovery optionality
- •The company's rare disease pipeline is narrowing to three assets (Orladeyo, navenibart phase 3, BCX17725 phase 1), with top-line navenibart data delayed until Q3 2027, creating a multi-year timeline to new revenue generation
- •Monitor Orladeyo competitive dynamics with KalVista's Ekterly and the outcome of navenibart phase 3 trial (Q3 2027)—both critical to validating BioCryst's pivot and partnership-driven growth strategy
BioCryst PharmaceuticalsKalVista PharmaceuticalsChiesi GroupOrladeyonavenibartBCX17725
→ Read original articleMarket Access•Fierce Biotech•Jun 29, 2026
Ipsen pens $1.7B deal to acquire Kartos for potential Jakafi add-on therapy for myelofibrosis
background ▾
- •Navtemadlin targets the TP53-driven subset of myelofibrosis patients resistant to standard-of-care Jakafi, a clinically validated but underserved population with earlier phase 1b/2 efficacy signals in 42% of patients.
- •Phase 3 readout expected in 2025 with potential 2028 approval; regulatory success hinges on whether the ~600-patient trial confirms clinical benefit in the TP53-mutant population and whether Ipsen can secure expedited pathways.
- •Watch for: phase 3 topline results in 2025; competitive landscape shifts if other p53 reactivators (e.g., PMV's rezatapopt) advance in hematologic malignancies; post-approval market sizing and payer reimbursement strategy for combination JAK + MDM2 inhibitor therapy.
IpsenKartos TherapeuticsIncytenavtemadlinJakafirezatapopt
→ Read original articleMarket Access•Fierce Biotech•Jun 29, 2026
UK-based Scancell bids to buy Nasdaq-listed Neuphoria to ‘increase profile’ with US investors
background ▾
- •Scancell's primary motivation appears to be accessing Nasdaq listing rather than acquiring Neuphoria's pipeline, signaling the deal is primarily strategically motivated for capital markets positioning
- •Neuphoria's lead program (soclenicant for social anxiety) has failed, but the company retains a Merck-partnered Alzheimer's disease program with substantial financial upside ($450M milestones), which could represent residual value to acquirers
- •Watch for final bid negotiations and whether Merck's partnership agreement contains change-of-control provisions that could affect deal economics or Neuphoria's ability to realize milestone payments post-acquisition
Scancell HoldingsNeuphoria TherapeuticsMerck & Co.soclenicantiSCIB1+Modi-1
→ Read original articleMarket Access•Fierce Biotech•Jun 29, 2026
Roche launches Axelios 1, its eagerly awaited gene sequencing rival to Illumina
background ▾
- •Roche's Axelios 1 directly challenges Illumina's market dominance in high-throughput sequencing with a differentiated nanopore-based platform promising speed, accuracy, and cost efficiency advantages
- •Strategic partnerships with major clinical and academic labs provide immediate validation and adoption pathways, while the research-only designation preserves a phased go-to-market strategy
- •Watch for: regulatory pathway toward clinical diagnostic clearance, comparative health economics data versus NovaSeq X, and adoption velocity among sequencing centers globally
RocheIlluminaHartwig Medical FoundationAxelios 1NovaSeq X
→ Read original articleMarket Access•KFF•Jun 30, 2026
AI: Show Me the Outcomes
background ▾
- •Current healthcare AI investment is heavily skewed toward administrative functions (billing, coding, risk adjustment) at ~60%, with minimal resources directed to direct care delivery and outcomes improvement
- •Value-based care models like Cityblock Health position outcome-focused AI as a cost-reduction strategy, particularly for underserved Medicaid populations and chronically ill patients
Cityblock Health
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Jun 29, 2026
Evommune’s phase 2b trial flops, ending challenge to Novartis in hives
background ▾
- •EVO756 missed primary endpoint in phase 2b CSU trial; none of three doses achieved statistical significance versus placebo on UAS7 at Week 12
- •Failure removes a meaningful near-term commercial threat to Novartis's newly launched Rhapsido and casts doubt on MRGPRX2 antagonism as a viable mechanism in itch-related indications
- •Watch for Q3 atopic dermatitis data and upcoming migraine trial initiation—both now carry low probability of success per analyst consensus; company stock fell 35% premarket
EvommuneNovartisIncyteEVO756RhapsidoEP262
→ Read original articleClinical Trials•Endpoints News•Jun 30, 2026
BeOne’s Brukinsa succeeds in frontline mantle cell lymphoma study
background ▾
- •Brukinsa achieved a 43% reduction in progression-free survival hazard versus chemoimmunotherapy in frontline mantle cell lymphoma, a meaningful clinical benefit in a treatment-naïve population
- •This result supports potential label expansion beyond Brukinsa's current approved uses, likely triggering regulatory submissions and opening a larger patient population
- •Monitor for full data presentation at upcoming oncology conferences and FDA submission timeline for the frontline indication
BeOne MedicinesBrukinsaacalabrutinib
→ Read original articleClinical Trials•Endpoints News•Jun 29, 2026
NEJM retracts pivotal data for Amgen's Tavneos
background ▾
- •NEJM retraction of pivotal Tavneos trial data undermines the primary evidence supporting the drug's efficacy claims and regulatory approval
- •This represents a severe reputational and commercial blow to Amgen, potentially affecting payer coverage decisions and clinical adoption even if the drug remains approved
- •Monitor for regulatory agency response (FDA), whether additional data are under investigation, and impact on ongoing or planned trials; assess reimbursement implications given payer reliance on published evidence
AmgenTavneosiptacopan
→ Read original articleClinical Trials•Endpoints News•Jun 29, 2026
Evommune's lead drug fails in chronic hives, stock sinks
background ▾
- •Lead drug failed primary endpoints in chronic hives trial, triggering significant shareholder loss and casting doubt on core pipeline strategy
- •First major clinical readout post-IPO indicates the market may have overvalued the company or underestimated clinical/translational risk
- •Watch for management commentary on remaining pipeline assets, cash runway, and potential strategic pivots or partnerships
Evommune
→ Read original article